CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on

Rolling NDA submission for zuranolone in MDD underway, with full submission expected to be completed in the second half of 2022, associated NDA submission in PPD planned for early 2023 Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD on track for mid-2022 Six planned and

The companies expect to complete submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression anticipated in the first half of 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 3, 2022 at 8:00 a.m.

Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at

Data Presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and efficacy of SAGE-718 once daily in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will

Rolling NDA submission for zuranolone in MDD expected to begin in early 2022 and planned to be completed in the second half of 2022 now supported by data from six positive clinical studies An associated NDA submission in PPD expected in 2023; Fast Track designation received for zuranolone in PPD

At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms Key secondary endpoint demonstrates zuranolone co-initiated with an antidepressant was statistically significant in reducing